Physician profile
David Duke
NPI 1437124757
$860.30
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $93.93 · 2021: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $284.96 | 2019-2021 | |
| Abbvie INC. | $166.75 | 2019-2021 | |
| Coloplast Corp | $92.13 | 2019-2020 | |
| Pfizer INC. | $84.75 | 2019-2020 | |
| Ethicon US, LLC | $80.99 | 2019 | |
| Abbott Laboratories | $63.25 | 2019 | |
| Covidien Lp | $35.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.34 | 2019 | |
| Therapeuticsmd, INC. | $12.06 | 2019 | |
| Mayne Pharma Commercial LLC | $11.68 | 2021 | |
| Merck Sharp & Dohme LLC | $11.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.